Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 6/20 | 0.43 |
| ▸ | BRD4 | O60885 | 3/20 | 0.43 |
| ▸ | JAK3 | P52333 | 6/20 | 0.42 |
| ▸ | WEE1 | P30291 | 3/20 | 0.41 |
| ▸ | PLK1 | P53350 | 2/20 | 0.41 |
| ▸ | MAP4K1 | Q92918 | 4/20 | 0.41 |
| ▸ | STAT6 | P42226 | 1/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.41 |
| ▸ | PAK4 | O96013 | 1/20 | 0.40 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15277152 | 0.91 | FGFR4 (0.45) | FGFR4JAK2BRD4JAK3WEE1 | |
| SCHEMBL15035650 | 0.80 | PAK4 (0.42) | JAK2BRD4JAK3WEE1MAP4K1 | |
| SCHEMBL15277138 | 0.80 | JAK2 (0.41) | JAK2BRD4JAK3WEE1PLK1 | |
| SCHEMBL15034782 | 0.77 | WEE1 (0.41) | JAK2BRD4JAK3WEE1MAP4K1 | |
| SCHEMBL15034882 | 0.77 | PAK4 (0.42) | JAK2BRD4JAK3WEE1MAP4K1 | |
| SCHEMBL15035011 | 0.77 | PTK2 (0.41) | JAK2BRD4JAK3WEE1MAP4K1 | |
| SCHEMBL15035866 | 0.76 | JAK2 (0.40) | JAK2BRD4JAK3WEE1MAP4K1 | |
| SCHEMBL15035897 | 0.75 | JAK2 (0.40) | JAK2BRD4JAK3WEE1PLK1 | |
| SCHEMBL15041414 | 0.75 | JAK2 (0.39) | JAK2BRD4JAK3WEE1PLK1 | |
| SCHEMBL15034931 | 0.74 | JAK3 (0.39) | JAK2BRD4JAK3WEE1MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130252967-A1 | 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252967-A1 | 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK3, PAK6 | FGFR4 2162/4885JAK2 227/4885BRD4 711/4885 |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | FGFR4 1949/4885JAK2 720/4885BRD4 1003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.